Advances in hepatitis C therapy: What is the current state - what come&rsquo;s next?

doi:10.4254/wjh.v8.i3.139

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9730)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

911

WORD

495

HTML

4562

Tables (1-4)

135

Sum=6103

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

441

Download

973

Sum=1414

Publishing Process of This Article

Item

Count

Browse

918

Download

1295

Sum=2213

Jan 28, 2016 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (54)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Hepatol. Jan 28, 2016; 8(3): 139-147
Published online Jan 28, 2016. doi: 10.4254/wjh.v8.i3.139

Table 1 Current recommendations of antiviral regimens depending on the genotype

DAA-regime	HCV-genotype
	1a	1b	2	3	4	5	6
SOF + R	(×)	(×)	×	×	(×)	(×)	(×)
SOF + SMV ± R	×	×			×
SOF + DCV¹± R	×	×	(×)	×	×
SOF + LDV ± R	×	×		(×)	×	×	×
OBV + PTV/r ± DSV ± R (3D)	×	×
OBV + PTV/r ± R (2D)					×

¹DCV, no approval in the United States. DAA: Direct antiviral agents; LDV: Ledipasvir; SMV: Simeprevir; DCV: Daclatasvir; SOF: Sofosbuvir; OBV: Ombitasvir; PTV: Paritaprevir; HCV: Hepatitis C virus; DSV: Dasabuvir; R: Ribavirin; r: Ritonavir.

Citation: Zopf S, Kremer AE, Neurath MF, Siebler J. Advances in hepatitis C therapy: What is the current state - what come’s next? World J Hepatol 2016; 8(3): 139-147
URL: https://www.wjgnet.com/1948-5182/full/v8/i3/139.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i3.139